NCT04646252

Brief Summary

The researchers intend to recruit individuals who are referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital, Athens According to institutional protocols, a detailed medical history for atherosclerotic risk factors and current medication is recorded and a baseline clinical examination is performed. Moreover fasting blood samples are drawn to diagnose the presence of diabetes mellitus and hyperlipidemia. Glycocalyx examination is performed at the same visit. The subjects are revaluated at one month and then followed up according to the attending physician's instructions. Pulse wave velocity and the rest pulse wave analysis parameters were also calculated to determine the additive predictive value for cardiovascular events beyond SCORE2. All subjects are followed up for adverse events (death, stroke, myocardial infarction, hospitalization for heart failure) for 6 years after enrollment via telephonic contact and planned appointment at the outpatient clinic.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
13mo left

Started Jan 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Jan 2013May 2027

Study Start

First participant enrolled

January 10, 2013

Completed
7.9 years until next milestone

First Submitted

Initial submission to the registry

November 22, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 27, 2020

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 20, 2026

Expected
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 28, 2027

Last Updated

May 29, 2024

Status Verified

May 1, 2024

Enrollment Period

13.4 years

First QC Date

November 22, 2020

Last Update Submit

May 28, 2024

Conditions

Keywords

perfused boundary regionprimary prevention of major cardiovascular eventsintegrity of endothelial glycocalyx

Outcome Measures

Primary Outcomes (1)

  • Major Adverse Cardiovascular events

    death of any cause, myocardial infarction (ICD-10: DI20-22), stroke (ICD-10: DI60-68; DG45) and hospitalization for heart failure (ICD-10: DI50-51; DI42; DI11).

    6 years

Interventions

Measurement of Perfused Boundary Region of sublingual microvessels to assess thickness of endothelial glycocalyx Measurement of Pulse Wave Velocity to quantify arterial stiffness

Also known as: pulse wave velocity, pulse wave analysis

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

As far as ethnicity is concerned, an individual is not considered Greek in case he/she was born abroad and also has at least a foreigner parent or he/she is born in Greece but both parents were foreigners. Inversely, a subject was considered Greek if they and simultaneously both parents were born in Greece..

You may qualify if:

  • We recruit individuals who were referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital.

You may not qualify if:

  • History of Coronary artery disease,
  • History of Peripheral Arterial Disease,
  • History of Heart failure
  • History of Stroke
  • hepatic failure
  • renal failure,
  • active neoplasia
  • poorly controlled DM, defined as Hba1C\>7%

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

"Attikon" University General Hospital

Athens, Attica, 12462, Greece

RECRUITING

Related Publications (1)

  • Ikonomidis I, Thymis J, Simitsis P, Koliou GA, Katsanos S, Triantafyllou C, Kousathana F, Pavlidis G, Kountouri A, Polyzogopoulou E, Katogiannis K, Vlastos D, Kostelli G, Triantafyllidi H, Parissis J, Papadavid E, Lekakis J, Filippatos G, Lambadiari V. Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study. J Cardiovasc Transl Res. 2022 Aug;15(4):890-902. doi: 10.1007/s12265-021-10180-2. Epub 2021 Oct 28.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Aliquots of serum and plasma

Study Officials

  • IGNATIOS IKONOMIDIS, PROFESSOR

    National and Kapodistrian University of Athens

    PRINCIPAL INVESTIGATOR

Central Study Contacts

IGNATIOS IKONOMIDIS

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

November 22, 2020

First Posted

November 27, 2020

Study Start

January 10, 2013

Primary Completion (Estimated)

June 20, 2026

Study Completion (Estimated)

May 28, 2027

Last Updated

May 29, 2024

Record last verified: 2024-05

Locations